Next Phase Newsletter

Your gateway to the largest pre-IPO capital investor community

By Karen Deyo, VP of Product, Israel BD, LSN

RESI Boston 2024 was a landmark event, setting new records for attendance and partnering for our Boston event. With over 2,000 official partnering meetings and hundreds more happening informally, the conference proved to be an invaluable platform for connecting investors and startups. Bringing together over 350 investors/in-licensors and 350 early-stage companies raising seed, Series A, and Series B funding, RESI Boston facilitated crucial partnerships that accelerate the journey of life-changing treatments to patients.

The RESI conference series offers a reliable way to fundraise and out-license for preclinical and clinical-stage companies year-round. With a unique 1:1 company-to-investor ratio, RESI events provide unparalleled access to investors and in-licensors, giving participants a significant edge in securing funding and forming vital partnerships. RESI also stands out as the partnering conference with the highest number of pre-IPO capital investors, making it a must-attend event for startups in the life sciences sector.

The investor panels at RESI Boston were a major attraction, with many sessions filled to standing room only. These panels allowed startups and stakeholders to hear directly from experienced investors, providing insights into the latest trends and opportunities in the industry. You can get a glimpse of the excitement of RESI Boston through this video from the event.

Hear from more investors and other attendees at RESI Boston.

This year, LSN added a new component to RESI Boston, with a Soft Landing event taking place the day before RESI Boston, providing insight into what it takes to relocate to the Boston ecosystem, and the benefits to companies of doing so. Looking forward, RESI Boston offers an ideal opportunity for companies to tap into the thriving Boston life science ecosystem, make meaningful connections, and secure the capital needed to advance their innovations. We are excited about the future and invite you to join us at upcoming RESI conferences to continue your journey of discovery, networking, and growth.

Don’t miss out on your chance to participate in the next RESI event. Whether you’re an investor looking to discover promising startups or an innovator seeking the right partnerships, RESI is the place to be. We hope to see you there!

By Greg Mannix, VP, EMEA Business Development, LSN

The Soft-Landing program, held at the Cambridge Innovation Center (CIC), offered an insightful look into how international companies can effectively establish a foothold in the U.S. life science market, with a focus on the Boston-Cambridge area—one of the world’s most significant hubs for life sciences. The event attracted over 100 registrants interested in commencing operations in the region. The CIC, which also presented during the event, provided an ideal backdrop as a key hub for regional innovation and collaboration.

The day started with introductions by Life Science Nation (LSN), providing an overview of the investor landscape and the crucial role it plays in supporting life sciences in the region. This was followed by MassBio’s presentation, emphasizing their efforts to fuel the ecosystem in Massachusetts, and an introduction to the Massachusetts Life Science Center highlighting their programs and significant resources that support incoming companies.

Legal considerations and steps for establishing a business in the U.S., including the Delaware flip, were covered by McDermott Will & Emery, providing valuable information for companies looking to set up in the United States. The CIC spoke about where to set up operations in Boston, and Abi Lab discussed opportunities beyond Kendall Square, offering a comprehensive view of the life science ecosystem in the Greater Boston area.

A networking lunch provided participants with the opportunity to connect with other attendees, forming connections and gaining additional insight.

In the afternoon, participants attended a CEO roundtable discussion that examined the pros and cons of being based in Greater Boston, followed by presentations from PwC on launching great science with great partnerships and Cambridge Scientific on securing lab space in the area. Polsinelli covered key patent and FDA considerations for navigating regulatory landscapes in the U.S., while Banc of California provided insights into banking and financial matters critical to establishing a successful presence in the country.

The program concluded with a networking reception, allowing participants to connect directly with industry leaders, potential partners, and fellow innovators. This session was an excellent opportunity to gain firsthand insights from key players in the Boston-Cambridge life science ecosystem and to make connections that could support their expansion efforts.

The Boston-Cambridge region, known for its world-class academic institutions, vibrant investor network, renowned healthcare facilities, and top-tier talent, provides an ideal environment for companies aiming to innovate and grow. For international companies seeking to enter the U.S. market, the Soft-Landing program offered an invaluable guide to leveraging these local resources for success.

By Max Braht, Business Development Manager (USA Midwest & Canada), LSN

As RESI Boston approaches next week, there’s still time to secure your spot! Whether you’re looking to attend virtually, take advantage of a one-day in-person pass, or join with an audience access pass, you can still register for the conference and begin scheduling meetings with over 350 investors and 350 innovators.

Registration Options:

• Full Virtual Pass: Join RESI’s virtual platform on September 26-27 with access to panels and 1-to-1 partnering meetings.
• One-Day In-Person Pass: Attend in-person on September 25 for a day and meet investors through scheduled meetings, live panels, and spontaneous networking.
• Audience Access Pass: Enjoy in-person experience on September 25 to gain access to panels, networking events, and investor content without full partnering features.

Register today to be part of the life science ecosystem and take advantage of valuable partnership opportunities.

Join RESI Boston now and explore all your registration options here!

RESI Boston 2024 Confirmed Investors

See more investors at resiconference.com.

By Greg Mannix, VP, EMEA Business Development, LSN

The Redefining Early Stage Investments (RESI) conference series is the gateway for start-ups and early-stage life science companies seeking strategic connections with global investors and industry partners. Designed to bridge the gap between fundraising companies and investors, RESI empowers life science entrepreneurs by connecting them to partners who align with their technology and stage of development.

Unlike other events, RESI crosses borders and domains, offering unparalleled access to 10 categories of investors across drugs, devices, diagnostics, and digital health (the “4 Ds”). Whether you’re an early-stage start-up seeking seed capital, or you’re advancing toward Series A or B funding, RESI’s unique structure opens doors to vital funding and partnerships across the globe.

Next Up: RESI London & Genesis 2024 – December 4-6

Mark your calendars for December 4, 2024, as RESI London and Genesis 2024 join forces in London. Taking place at 1 Wimpole Street and 11 Cavendish Square, this co-located event will be packed with opportunities to network, engage in keynotes and panels, and participate in the Innovator’s Pitch Challenge (IPC), where presenting companies will receive feedback from seasoned investors.

Following the in-person event, two days of virtual partnering (December 5-6) will expand your networking potential even further, allowing you to connect with global investors from anywhere in the world. This hybrid structure ensures that you can maximize your visibility and opportunities with key stakeholders throughout the life science sector. Enjoy exclusive discounts by registering for both events.

Looking Ahead: RESI JPM 2025 – January 14-16

Kick off the new year by joining us at the 50th RESI Conference, co-located with the prestigious JPM Healthcare Conference in San Francisco. Taking place on January 14, 2025, at the San Francisco Marriott Marquis, RESI JPM will offer an in-person event featuring the Innovator’s Pitch Challenge and 1-to-1 partnering with over 500 investors. The conference will then transition to two days of online meetings, broadening your ability to build relationships and secure deals. Save $800 with super early bird rates when you register by October 4.

Past RESI JPM events have drawn thousands of attendees, making it a prime opportunity for early-stage life science innovators to network with investors and industry experts who are eager to discover and support breakthrough technologies. By participating in RESI, companies can unlock meaningful connections with top-tier investors and partners while advancing their efforts in the fast-paced and ever-evolving life science landscape.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation’s RESI Boston is just around the corner, and excitement is building for the Innovator’s Pitch Challenge (IPC). This year, we are thrilled to feature 56 innovative startups across 14 sessions, each dedicated to a specific sector or subsector within the life sciences.

The LSN team has been hard at work recruiting a panel of active investors and industry experts to serve as judges for the pitches. These judges have been invited to participate based on their experience, investment interests, and areas of expertise, ensuring that each session is tailored to the right audience.

We are excited to introduce the esteemed IPC pitch judges who will be lending their insights and expertise at RESI Boston. Their participation adds immense value to the event, offering startups the chance to receive invaluable feedback and explore new avenues for funding their ideas.

Below is a list of IPC pitch judges at RESI Boston:

Featured RESI Boston IPC Pitch Judges
Chris Aleong Vice President BioIdeations	Peter Alff Senior Venture Partner Orange Grove Bio	Anjan Aralihalli Member of Board of Directors Muscular Dystrophy Association	Giulia Balconi Investor Adjuvant Capital
Michael Benezra Managing Partner & Founder Erez Capital	Carmelida Capaldi Innovation Project Manager Chiesi	James Carroll Managing Director for Life Science Investments Wharton Alumni Angels	Doug Cary Founder and Principal Meritage Technologies
Jeffrey Champagne Screening Committee Boston Harbor Angels	Shailesh Chavan Managing Partner Transatlantic Life Science Venture	Nicolas Cindric Partner Yahara Ventures	David Fogel Member of Screening & Due Diligence Committees Mass Medical Angels
Emily Gaudiano Investment Associate SV Health Investors	Henry Huang Head, Strategy Marketing Autobio Venture Capital	Brendan Hussey Vice President JLS Fund	Ehsan Jabbarzadeh Venture Partner IAG Capital Partners
Jennifer Jordan Venture Partner iGlobe Partners	Jeff Knox Senior Associate Innospark Ventures	Uplaksh KumarForesite Capital	Claire Leurent Managing Director AbbVie Ventures
Carlos Medina Senior Associate SIC Venture Studio	Jose Navarro Scientific Director & Partner quadraScope Venture Fund	Kim Nearing Venture Partner BioVeda China Fund (BVCF)	Shinji Okitsu External Immunology Lead North America and China Sanofi
Aaron Ray Partner 5 Horizons Capital	Joe Rogers Venture Partner, Digital Health Tenmile	James Simmons Associate Director Business Development Kowa Research Institute, Inc.	Manbir Singh Program Manager Biomedical Advanced R&D Authority (BARDA)
Adam Steinert CTO Yahara Ventures	Wei Tao Board Director & Chair, Bio/Genomics Life Science Angels	Mike Thomas Managing Partner Bold Brain Capital	Natalia Ulyanova Director, Business Development, Oncology Astellas Pharma
Mark Vreeke Co-Founder Chemical Angel Network	Christopher Whitfield Partner Syridex Bio	Hong Xin Senior Director, External Innovation, Search & Evaluation Johnson & Johnson Innovation	Hao Xing Associate MPM Capital
Chris Yoo General Partner and Managing Director Xcellerant Ventures	Join RESI Boston to Meet More Investors or Investor Judges